WGS vs. SHCR, DCGO, TALK, INNV, PNTG, RCEL, TSVT, XERS, TELO, and TLSI
Should you be buying GeneDx stock or one of its competitors? The main competitors of GeneDx include Sharecare (SHCR), DocGo (DCGO), Talkspace (TALK), InnovAge (INNV), The Pennant Group (PNTG), AVITA Medical (RCEL), 2seventy bio (TSVT), Xeris Biopharma (XERS), Telomir Pharmaceuticals (TELO), and TriSalus Life Sciences (TLSI). These companies are all part of the "medical" sector.
GeneDx (NASDAQ:WGS) and Sharecare (NASDAQ:SHCR) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their media sentiment, community ranking, risk, analyst recommendations, valuation, institutional ownership, profitability, earnings and dividends.
61.7% of GeneDx shares are owned by institutional investors. Comparatively, 35.1% of Sharecare shares are owned by institutional investors. 28.1% of GeneDx shares are owned by company insiders. Comparatively, 29.3% of Sharecare shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
GeneDx has a beta of 2.75, indicating that its stock price is 175% more volatile than the S&P 500. Comparatively, Sharecare has a beta of 0.26, indicating that its stock price is 74% less volatile than the S&P 500.
Sharecare received 5 more outperform votes than GeneDx when rated by MarketBeat users. Likewise, 35.29% of users gave Sharecare an outperform vote while only 20.00% of users gave GeneDx an outperform vote.
In the previous week, Sharecare had 12 more articles in the media than GeneDx. MarketBeat recorded 19 mentions for Sharecare and 7 mentions for GeneDx. GeneDx's average media sentiment score of 0.53 beat Sharecare's score of 0.28 indicating that GeneDx is being referred to more favorably in the media.
GeneDx currently has a consensus target price of $13.00, suggesting a potential upside of 17.33%. Sharecare has a consensus target price of $1.00, suggesting a potential upside of 23.46%. Given Sharecare's higher probable upside, analysts plainly believe Sharecare is more favorable than GeneDx.
Sharecare has higher revenue and earnings than GeneDx. Sharecare is trading at a lower price-to-earnings ratio than GeneDx, indicating that it is currently the more affordable of the two stocks.
Sharecare has a net margin of -28.86% compared to GeneDx's net margin of -86.77%. Sharecare's return on equity of -17.11% beat GeneDx's return on equity.
Summary
Sharecare beats GeneDx on 11 of the 18 factors compared between the two stocks.
Get GeneDx News Delivered to You Automatically
Sign up to receive the latest news and ratings for WGS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding WGS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
